Premium
Short‐term changes in bone formation markers following growth hormone ( GH ) treatment in short prepubertal children with a broad range of GH secretion
Author(s) -
Andersson Björn,
SwolinEide Diana,
Magnusson Per,
AlbertssonWikland Kerstin
Publication year - 2015
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.12499
Subject(s) - osteocalcin , medicine , endocrinology , bone remodeling , procollagen peptidase , radioimmunoassay , type i collagen , alkaline phosphatase , biology , biochemistry , enzyme
Summary Objectives Growth hormone ( GH ) promotes longitudinal growth and bone modelling/remodelling. This study investigated the relationship between levels of bone formation markers and growth during GH treatment in prepubertal children with widely ranging GH secretion levels. Methods The study group comprised 113 short prepubertal children (mean age ± SD, 9·37 ± 2·13 years; 99 boys) on GH treatment (33·0 ± 0·06 μg/kg/day) for 1 year. Blood samples were taken at baseline and 1 and 2 weeks, 1 and 3 months, and 1 year after treatment start. Intact amino‐terminal propeptide of type I procollagen ( PINP ), bone‐specific alkaline phosphatase ( BALP ) and osteocalcin were measured using an automated IDS ‐ iSYS immunoassay system. Results Intact amino‐terminal propeptide of type I procollagen ( PINP ), BALP and osteocalcin, increased in the short‐term during GH treatment. PINP after 1 week ( P = 0·00077), and BALP and osteocalcin after 1 month ( P < 0·0001 and P = 0·0043, respectively). PINP levels at 1 and 3 months correlated positively, and osteocalcin levels at 1 week and percentage change after 1 month correlated negatively, with first year growth response. No significant correlations were found between BALP and first year growth. Multiple regression analysis showed that bone marker levels together with auxological data and insulin‐like growth factor binding protein‐3 explained the variation in first year growth response to 36% at start, 32% after 2 weeks and 48% at 3 months. Conclusion Short‐term increases in levels of the bone formation markers PINP , BALP and osteocalcin showed different temporal patterns, but all correlated with first year growth response during GH treatment. These markers may be a useful addition to existing prediction models for growth response.